Keros Therapeutics Inc’s filing revealed that its 10% Owner ADAR1 Capital Management, LLC acquired Company’s shares for reported $9.46 million on Apr 09 ’25. In the deal valued at $10.13 per share,934,258 shares were bought. As a result of this transaction, ADAR1 Capital Management, LLC now holds 4,392,737 shares worth roughly $53.5 million.
Then, GORDON CARL L sold 250,000 shares, generating $11,002,500 in total proceeds. Upon selling the shares at $44.01, the Director now owns 119,522 shares.
Before that, ORBIMED ADVISORS LLC sold 250,000 shares. Keros Therapeutics Inc shares valued at $11,002,500 were divested by the Director at a price of $44.01 per share. As a result of the transaction, ORBIMED ADVISORS LLC now holds 119,522 shares, worth roughly $1.46 million.
Cantor Fitzgerald downgraded its Keros Therapeutics Inc [KROS] rating to a Neutral from a an Overweight in a research note published recently. A number of analysts have revised their coverage, including Wedbush’s analysts, who decreased its forecast for the stock in mid January from “an Outperform” to “a Neutral”. Oppenheimer also remained covering KROS and reiterated its “an Outperform” recommendation on December 16, 2024. Guggenheim revised its rating on December 16, 2024. It rated KROS as “a Neutral” which previously was an “a Buy”.
Price Performance Review of KROS
On Friday, Keros Therapeutics Inc [NASDAQ:KROS] saw its stock fall -0.49% to $12.18. Over the last five days, the stock has gained 22.04%. Keros Therapeutics Inc shares have fallen nearly -23.06% since the year began. Nevertheless, the stocks have fallen -79.98% over the past one year. While a 52-week high of $72.37 was reached on 01/02/25, a 52-week low of $9.12 was recorded on 04/09/25. SMA at 50 days reached $10.97, while 200 days put it at $37.07.
Levels Of Support And Resistance For KROS Stock
The 24-hour chart illustrates a support level at 11.93, which if violated will result in even more drops to 11.68. On the upside, there is a resistance level at 12.43. A further resistance level may holdings at 12.68. The Relative Strength Index (RSI) on the 14-day chart is 61.29, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.97, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 9.47%. Stochastics %K at 77.03% indicates the stock is a holding.
How much short interest is there in Keros Therapeutics Inc?
A steep rise in short interest was recorded in Keros Therapeutics Inc stocks on 2025-03-31, dropping by -0.13 million shares to a total of 4.05 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 4.18 million shares. There was a decline of -3.18%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 13, 2024 when H.C. Wainwright resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $47.
